drugset / Trial / NCT06540326
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Guidelines recommend FOLFIRI in combination with bevacizumab or cetuximab as a treatment option for advanced second-line colorectal cancer, and this study explores the efficacy and safety of a clinical study of liposomal irinotecan (II), fluorouracil, in combination with bevacizumab or cetuximab for the second-line treatment of patients with advanced colorectal cancer.
Timeline
- Start
- 2024-11-12
- Primary completion
- 2026-04-15
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | fluorouracil | Small molecule | — | — |
| Subject | irinotecan liposome (II) | Unknown | — | — |